Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CGTX
CGTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CGTX News
Cognition Therapeutics Discusses Positive Path Forward with FDA for Zervimesine Registration
May 21 2026
Newsfilter
Cognition Therapeutics Secures New Donation to Extend EAP for DLB Patients
May 14 2026
Newsfilter
Cognition Therapeutics Q1 Earnings Beat Expectations
May 07 2026
seekingalpha
Cognition Therapeutics CEO to Present at Needham Conference
Apr 07 2026
Newsfilter
Cognition Therapeutics Advances CT1812 to Late-Stage Trials for DLB Psychosis
Mar 31 2026
Newsfilter
Cognition Therapeutics Reports Better-Than-Expected FY GAAP EPS
Mar 26 2026
seekingalpha
Cognition Therapeutics Advances Zervimesine Clinical Development for DLB Psychosis
Mar 26 2026
Newsfilter
COGNITION THERAPEUTICS INC: FDA PSYCHIATRY DIVISION MEETING ANTICIPATED BY MID-2026
Mar 26 2026
moomoo
Cognition Therapeutics Reports FY Operating Loss of USD 47.799 Million
Mar 26 2026
moomoo
Cognition Advances Zervimesine Development for DLB Psychosis Treatment
Mar 02 2026
Newsfilter
Cognition Extends Expanded Access Program for DLB
Feb 05 2026
Newsfilter
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
Dec 17 2025
NASDAQ.COM
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Nov 26 2025
NASDAQ.COM
HC Wainwright & Co. Affirms Buy Rating for Cognition Therapeutics, Keeps $3 Price Target Intact
Nov 19 2025
Benzinga
Cognition Therapeutics Finishes Participant Enrollment for Phase 2 Trial of Zervimesine (CT1812) in Early Alzheimer's Disease
Nov 13 2025
Newsfilter
CGTX, RVPH, SHOT, SONN, AKTX Surge in After-Hours Trading Following Clinical Developments and Fed Rate Cut Expectations
Sep 18 2025
NASDAQ.COM
Show More News
